• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Management of biochemical recurrence after radical prostatectomy for prostate cancer: A case report.前列腺癌根治术后生化复发的管理:一例报告。
Medicine (Baltimore). 2019 Jul;98(27):e16351. doi: 10.1097/MD.0000000000016351.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.雄激素剥夺治疗联合挽救性放疗用于前列腺癌根治术后生化复发患者。
Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30.
4
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.早期挽救性放疗后生化复发的前列腺癌患者应用同期雄激素剥夺治疗:一项大型多机构系列研究的长期结果。
Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.
5
Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.根治性前列腺切除术后可观察到生化复发而无需挽救治疗的患者类型。
World J Urol. 2020 Jul;38(7):1749-1756. doi: 10.1007/s00345-019-02970-w. Epub 2019 Sep 26.
6
Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.前列腺癌初次根治性治疗后生化复发的管理:综述
Urol Int. 2018;100(3):251-262. doi: 10.1159/000481438. Epub 2017 Nov 21.
7
HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.高强度聚焦超声作为根治性前列腺切除术后触诊、经直肠超声证实的局部复发性前列腺癌的一线挽救性治疗:一项初步研究。
Urol Oncol. 2012 Sep;30(5):577-83. doi: 10.1016/j.urolonc.2010.08.019. Epub 2011 Feb 2.
8
Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.在接受根治性前列腺切除术治疗的pN1前列腺癌患者中,与挽救性放射治疗相比,辅助性放射治疗与更好的肿瘤学结果相关。
BJU Int. 2017 May;119(5):717-723. doi: 10.1111/bju.13679. Epub 2016 Nov 21.
9
Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.前列腺癌挽救性放射治疗后“二次”生化复发的自然病程:一项多机构研究。
BJU Int. 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5.
10
Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.根治性前列腺切除术后生化复发患者早期挽救性放疗后结局的预测。
Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

引用本文的文献

1
Correlation between the expressions of metastasis-associated factor-1 in colon cancer and vacuolar ATP synthase.结肠癌中转移相关因子-1的表达与液泡ATP合酶之间的相关性
World J Gastrointest Surg. 2023 Nov 27;15(11):2463-2469. doi: 10.4240/wjgs.v15.i11.2463.

本文引用的文献

1
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-ESTRO-SIOG 前列腺癌诊治指南。第 1 部分:筛查、诊断及有治愈意图的局部治疗。
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
2
Peer review of cancer multidisciplinary teams: is it acceptable in Australia?癌症多学科团队的同行评议:在澳大利亚是否可行?
Med J Aust. 2015 Feb 16;202(3):144-7. doi: 10.5694/mja14.00768.
3
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者(COU-AA-302):一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
4
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.预测前列腺癌根治术后生化复发男性前列腺癌特异性死亡率的列线图
Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.
5
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
6
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.根治性前列腺切除术后生化复发后的临床进展长期风险:从手术到复发时间的影响。
Eur Urol. 2011 Jun;59(6):893-9. doi: 10.1016/j.eururo.2011.02.026. Epub 2011 Feb 22.
7
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中,泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
8
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
9
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.
10
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.姑息性经尿道前列腺切除术治疗局部晚期前列腺癌患者的膀胱出口梗阻
J Urol. 2004 Feb;171(2 Pt 1):668-71. doi: 10.1097/01.ju.0000104845.24632.92.

前列腺癌根治术后生化复发的管理:一例报告。

Management of biochemical recurrence after radical prostatectomy for prostate cancer: A case report.

作者信息

Shen Jiayan, Zang Shoumei, Yu Xiaokai, Zhao Feng, Jiang Peng, Zhong Baishu, Zhou Hua, Yan Senxiang

机构信息

Department of Radiation Oncology.

Department of Urology.

出版信息

Medicine (Baltimore). 2019 Jul;98(27):e16351. doi: 10.1097/MD.0000000000016351.

DOI:10.1097/MD.0000000000016351
PMID:31277192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6635272/
Abstract

RATIONAL

How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Multiple disciplinary team (MDT) mechanism may propose an appropriate treatment plan for patients and can effectively improve patient prognosis and survival, reduce patient diagnosis and treatment waiting time, and greatly improve patient satisfaction.

PATIENT CONCERNS

Here, we presented a case of a 77-year-old man with a persistently elevated serum level of prostate-specific antigen (PSA), who had a history of radical prostatectomy (RP) and of 9 years endocrine therapy.

DIAGNOSES

Castration-resistant prostate cancer and locally recurrent prostate cancer.

INTERVENTIONS

Androgen-deprivation therapy was first utilized 2 months after RP, due to the consideration of BCR on May 5, 2007. And during the next 9 years, he was treated with different endocrine agents but failed to maintain serum levels of PSA stable. Finally, the MDT suggested patient to perform salvage radiation therapy (SRT). Under MDT mechanism, we avoid secondary surgery, so as to reduce the patients' mental suffering and cost of patient care.

OUTCOMES

EPIC26 scale assessment revealed leak-free urine, good urine control, no defecation abnormalities or blood in the stool, no breast tenderness and breast enlargement significantly improved. The patient now has no adjuvant therapy, including endocrine therapy. The patient achieved good prognosis through local RT.

LESSONS

Pelvic SRT for patients with locally recurrent PCa may restore the same radical effect as RP. And more importantly, MDT mechanism plays an important role in making the most appropriate decisions for patients.

摘要

理论依据

对于原发性根治性治疗后出现生化复发(BCR)的前列腺癌(PCa)患者,如何进行管理是一个存在争议的问题。多学科团队(MDT)机制可为患者提出合适的治疗方案,能有效改善患者预后和生存率,减少患者诊断和治疗等待时间,并极大提高患者满意度。

患者关注

在此,我们介绍了一例77岁男性患者,其血清前列腺特异性抗原(PSA)水平持续升高,有根治性前列腺切除术(RP)病史及9年内分泌治疗史。

诊断

去势抵抗性前列腺癌和局部复发性前列腺癌。

干预措施

由于考虑到2007年5月5日出现BCR,RP术后2个月首次采用雄激素剥夺治疗。在接下来的9年里,他接受了不同的内分泌药物治疗,但未能维持PSA血清水平稳定。最后,MDT建议患者进行挽救性放射治疗(SRT)。在MDT机制下,我们避免了二次手术,从而减轻了患者的精神痛苦和医疗护理成本。

结果

EPIC26量表评估显示无尿漏、控尿良好、无排便异常或便血、无乳房压痛且乳房增大明显改善。患者目前无需辅助治疗,包括内分泌治疗。患者通过局部放疗获得了良好的预后。

经验教训

对于局部复发性PCa患者,盆腔SRT可能恢复与RP相同的根治效果。更重要的是,MDT机制在为患者做出最合适的决策中发挥着重要作用。